LLY stock icon

Eli Lilly
LLY

$878.29
1.07%

Market Cap: 835B

 

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Employees: 43,000

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 49 analysts
0
News positive %
of 158 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

85% more first-time investments, than exits

New positions opened: 334 | Existing positions closed: 181

50% more funds holding in top 10

Funds holding in top 10: 296 [Q4 2023] → 445 (+149) [Q1 2024]

31% more capital invested

Capital invested by funds: $456B [Q4 2023] → $598B (+$141B) [Q1 2024]

5% more funds holding

Funds holding: 3,178 [Q4 2023] → 3,331 (+153) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 1,365 | Existing positions reduced: 1,248

5% more call options, than puts

Call options by funds: $7.83B | Put options by funds: $7.46B

1.19% less ownership

Funds ownership: 70.97% [Q4 2023] → 69.78% (-1.19%) [Q1 2024]

Research analyst outlook

49 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$630
28%
downside
Avg. target
$866
1%
downside
High target
$1,025
17%
upside

49 analyst ratings

47 positive
96%
neutral
4%
negative
0%
Cantor Fitzgerald
Louise Chen
1%upside
$885
Overweight
Reiterated
15 Jul 2024
Berenberg
Kerry Holford
14%upside
$1000
Buy
Maintained
11 Jul 2024
JP Morgan
Chris Schott
14%upside
$1000
Overweight
Maintained
11 Jul 2024
Barclays
Carter Gould
17%upside
$1025
Overweight
Maintained
10 Jul 2024
Morgan Stanley
Terence Flynn
16%upside
$1023
Overweight
Maintained
5 Jul 2024

Financial journalist opinion

Based on 158 articles about LLY published over the past 30 days